|
EIF2A expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 8.84159999992029E-07 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
2.23629999995811E-06 |
| Normal-vs-Stage2 |
2.535300E-03 |
| Normal-vs-Stage3 |
1.21730000002263E-06 |
| Normal-vs-Stage4 |
1.459870E-03 |
| Stage1-vs-Stage2 |
6.621000E-01 |
| Stage1-vs-Stage3 |
2.537000E-01 |
| Stage1-vs-Stage4 |
4.904000E-01 |
| Stage2-vs-Stage3 |
2.706400E-01 |
| Stage2-vs-Stage4 |
8.637400E-01 |
| Stage3-vs-Stage4 |
1.642970E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
2.04050000229827E-08 |
| Normal-vs-AfricanAmerican |
9.206200E-02 |
| Normal-vs-Asian |
2.184400E-04 |
| Caucasian-vs-AfricanAmerican |
4.537600E-02 |
| Caucasian-vs-Asian |
5.668400E-01 |
| AfricanAmerican-vs-Asian |
1.714640E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
3.71410000000738E-05 |
| Normal-vs-Female |
1.18199999998847E-06 |
| Male-vs-Female |
9.288000E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
2.14209999999104E-05 |
| Normal-vs-Age(41-60Yrs) |
2.32769999997107E-06 |
| Normal-vs-Age(61-80Yrs) |
4.10029999999839E-05 |
| Normal-vs-Age(81-100Yrs) |
1.161700E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
6.564000E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
9.061400E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
6.504600E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
6.090000E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
7.575000E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
5.889800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
5.710000E-01 |
| Classical-VS-Follicular |
3.946800E-01 |
| Classical-VS-Other |
6.804000E-01 |
| Classical-VS-Normal |
2.62919999993727E-07 |
| Tall-VS-Follicular |
2.959200E-01 |
| Tall-VS-Other |
9.153800E-01 |
| Tall-VS-Normal |
3.580300E-04 |
| Follicular-VS-Other |
5.970800E-01 |
| Follicular-VS-Normal |
5.044700E-03 |
| Other-VS-Normal |
2.907900E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
2.20269999995359E-06 |
| Normal-vs-N1 |
2.67720000002303E-06 |
| N0-vs-N1 |
6.111400E-01 |
|
|
